CL2022001079A1 - Métodos y composiciones para el tratamiento del síndrome de rett - Google Patents

Métodos y composiciones para el tratamiento del síndrome de rett

Info

Publication number
CL2022001079A1
CL2022001079A1 CL2022001079A CL2022001079A CL2022001079A1 CL 2022001079 A1 CL2022001079 A1 CL 2022001079A1 CL 2022001079 A CL2022001079 A CL 2022001079A CL 2022001079 A CL2022001079 A CL 2022001079A CL 2022001079 A1 CL2022001079 A1 CL 2022001079A1
Authority
CL
Chile
Prior art keywords
methods
rett syndrome
compositions
treatment
trofinetide
Prior art date
Application number
CL2022001079A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence Irwin Glass
Mon Darwish
James M Youakim
Nancy Elizabeth Jones
Sean Paul Oosterholt
Oscar Della Pasqua
Original Assignee
Neuren Pharmaceuticals Ltd
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd, Acadia Pharm Inc filed Critical Neuren Pharmaceuticals Ltd
Publication of CL2022001079A1 publication Critical patent/CL2022001079A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Peptides Or Proteins (AREA)
CL2022001079A 2019-10-28 2022-04-28 Métodos y composiciones para el tratamiento del síndrome de rett CL2022001079A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962927008P 2019-10-28 2019-10-28
US202063031201P 2020-05-28 2020-05-28

Publications (1)

Publication Number Publication Date
CL2022001079A1 true CL2022001079A1 (es) 2023-04-21

Family

ID=75715568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001079A CL2022001079A1 (es) 2019-10-28 2022-04-28 Métodos y composiciones para el tratamiento del síndrome de rett

Country Status (14)

Country Link
US (1) US20220339138A1 (cg-RX-API-DMAC7.html)
EP (1) EP4051308A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022553888A (cg-RX-API-DMAC7.html)
KR (1) KR20220106982A (cg-RX-API-DMAC7.html)
CN (1) CN115335071A (cg-RX-API-DMAC7.html)
AU (1) AU2020376801A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008095A2 (cg-RX-API-DMAC7.html)
CA (1) CA3156680A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001079A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022007501A2 (cg-RX-API-DMAC7.html)
IL (1) IL292617B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004785A (cg-RX-API-DMAC7.html)
TW (1) TW202116300A (cg-RX-API-DMAC7.html)
WO (1) WO2021086892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287750A1 (en) 2021-07-12 2023-01-19 Acadia Pharmaceuticals Inc. Crystalline forms of trofinetide
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
WO2025262646A1 (en) * 2024-06-22 2025-12-26 Biophore India Pharmaceuticals Pvt. Ltd Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
LT2667715T (lt) * 2011-01-27 2017-11-10 Neuren Pharmaceuticals Limited Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
SI3024463T1 (sl) * 2013-07-25 2020-08-31 Neuren Pharmaceuticals Limited Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
GB2554064B (en) * 2016-09-01 2019-11-20 Jit Singh Shailinder An enteral feeding tube

Also Published As

Publication number Publication date
JP2025148461A (ja) 2025-10-07
AU2020376801A1 (en) 2022-06-09
IL292617B1 (en) 2025-11-01
WO2021086892A1 (en) 2021-05-06
BR112022008095A2 (pt) 2022-07-12
TW202116300A (zh) 2021-05-01
CA3156680A1 (en) 2021-05-06
US20220339138A1 (en) 2022-10-27
IL292617A (en) 2022-07-01
CO2022007501A2 (es) 2022-08-30
EP4051308A4 (en) 2023-08-23
EP4051308A1 (en) 2022-09-07
IL292617B2 (en) 2026-03-01
KR20220106982A (ko) 2022-08-01
JP2022553888A (ja) 2022-12-26
CN115335071A (zh) 2022-11-11
MX2022004785A (es) 2022-05-16

Similar Documents

Publication Publication Date Title
CO2022007501A2 (es) Métodos y composiciones para el tratamiento del síndrome de rett
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MX388408B (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2016013245A (es) Regimen de dosificacion de liberacion inmediata de moduladores s1p.
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a